Bornhäuser, M <br/><br/>
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.  [electronic resource] 

 -  Annals of hematology  2004 
 - S61-4 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0939-5555 
<br/><br/><label>Standard No.: </label>10.1007/s00277-004-0850-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD--analysis<br/>Antigens, CD34--analysis<br/>Benzamides<br/>Bone Marrow Cells--drug effects<br/>Cell Line, Tumor<br/>Cytarabine--pharmacology<br/>Gene Deletion<br/>Genes, abl--genetics<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia--genetics<br/>Piperazines--pharmacology<br/>Pyrimidines--pharmacology